Concepedia

Zhiqiang Meng

ZM

Statistics

Publications

119

Citations

10.5K

H-Index

48

Active since

2009

Affiliations

Fudan University Shanghai Cancer Center(Current)

Shanghai Medical College of Fudan University

Fudan University

Zhongshan Hospital

Anhui Medical University

Zhiqiang Meng is an author at Fudan University Shanghai Cancer Center specializing in oncology, medicine, and molecular oncology.

ORCID

Publications per year

2009–2025

119

Publications

119

Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study

Zhenggang Ren, Jianming Xu, Yuxian Bai et al. · The Lancet Oncology · 2021 · 1.1K citations

, , +13

A novel systemic inflammation response index (SIRI) for predicting the survival of patients with pancreatic cancer after chemotherapy

Qi Qi, Liping Zhuang, Yehua Shen et al. · Cancer · 2016 · 715 citations · Full text

, , +16

Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial

Shukui Qin, Zhenggang Ren, Zhiqiang Meng et al. · The Lancet Oncology · 2020 · 638 citations

, , +9

Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition)

Jian Zhou, Hui‐Chuan Sun, Zheng Wang et al. · Liver Cancer · 2023 · 452 citations · Full text

, , +12

Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

Josep M. Llovet, Masatoshi Kudo, Philippe Merle et al. · The Lancet Oncology · 2023 · 421 citations · Full text

, , +12

1–5 of 119